- Home
- AIO vs CGEM Comparison
AIO vs CGEM Comparison
Compare AIO & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AIO | CGEM |
|---|---|---|
| Founded | 2019 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 927.8M | 904.7M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | AIO | CGEM |
|---|---|---|
| Price | $26.29 | $13.22 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $30.13 |
| AVG Volume (30 Days) | 80.6K | ★ 1.0M |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | ★ 9.05% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $5.20 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $20.91 | $5.68 |
| 52 Week High | $27.67 | $16.74 |
Technical Indicators
Market Signals| Indicator | AIO | CGEM |
|---|---|---|
| Relative Strength Index (RSI) | 54.57 | 38.87 |
| Support Level | $23.89 | $11.92 |
| Resistance Level | $26.67 | $16.31 |
| Average True Range (ATR) | 0.48 | 1.10 |
| MACD | -0.09 | -0.24 |
| Stochastic Oscillator | 51.54 | 19.91 |
Price Performance
Historical ComparisonAbout AIO Virtus Artificial Intelligence & Technology Opportunities Fund of Beneficial Interest
Virtus Artificial Intelligence & Technology Opportunities Fund is a diversified, limited-term, closed-end management investment company. Its investment objective is to provide total return through a combination of current income, current gains, and long-term capital appreciation.
About CGEM Cullinan Oncology Inc.
Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.